PMID- 24396420
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20211021
IS  - 1792-0981 (Print)
IS  - 1792-1015 (Electronic)
IS  - 1792-0981 (Linking)
VI  - 7
IP  - 2
DP  - 2014 Feb
TI  - Effects of BD1047, a sigma(1) receptor antagonist, on the expression of mTOR, Camk2gamma 
      and GSK-3beta in fluvoxamine-treated N2a cells.
PG  - 435-438
AB  - Fluvoxamine, a common antidepressant agent, is designed to exert its 
      pharmacological effect by inhibiting synaptic serotonin reuptake. However, 
      increasing evidence has demonstrated that sigma(1) receptors are likely to be 
      involved in the mechanism of action of fluvoxamine. The present study aimed to 
      observe the effects of fluvoxamine on the expression levels of mammalian target 
      of rapamycin (mTOR), Ca(2+)/calmodulin-dependent protein kinase 2gamma (Camk2gamma) and 
      glycogen synthase kinase-3beta (GSK-3beta) in fluvoxamine-treated N2a cells and 
      attempted to elucidate whether sigma(1) receptors mediate the pharmacological effects 
      of fluvoxamine. The N2a cells were randomly divided into three groups (each n=6): 
      DMEM group (D group), 0.5 mumol/l fluvoxamine group (F group) and 0.2 mumol/l 
      BD1047 (a sigma(1) receptor antagonist) + 0.5 mumol/l fluvoxamine group (BF group). 
      Western blotting was used to determine the expression levels of mTOR, Camk2gamma and 
      GSK-3beta in the cultured N2a cells after two days of incubation. The F group 
      exhibited significant increases in the expression levels of mTOR and Camk2gamma and a 
      significant reduction in the expression levels of GSK-3beta compared with those in 
      the D group (P<0.01). By contrast, the BF group demonstrated significant 
      reductions in the expression levels of mTOR and Camk2gamma and a significant increase 
      in the expression levels of GSK-3beta, compared with those in the F group (P<0.01). 
      These results suggest that sigma(1) receptors mediate fluvoxamine-elicited changes in 
      the expression levels of mTOR, Camk2gamma and GSK-3beta in N2a cells, which indicates 
      that sigma(1) receptors are likely to be involved in the pharmacological effects of 
      fluvoxamine.
FAU - Su, Dong-An
AU  - Su DA
AD  - Department of Anesthesiology, The PLA 102 Hospital, Second Military Medical 
      University, Changzhou, Jiangsu 213003, P.R. China.
FAU - Jiang, Ri-Yue
AU  - Jiang RY
AD  - Department of Radiation Oncology, The Third Affiliated Hospital of Soochow 
      University, Changzhou, Jiangsu 213003, P.R. China.
FAU - Liu, Ning
AU  - Liu N
AD  - Department of Critical Care Medicine, The Third Affiliated Hospital of Soochow 
      University, Changzhou, Jiangsu 213003, P.R. China.
FAU - Ding, Liang-Cai
AU  - Ding LC
AD  - Department of Critical Care Medicine, The Third Affiliated Hospital of Soochow 
      University, Changzhou, Jiangsu 213003, P.R. China.
FAU - Wang, DA-Ming
AU  - Wang DM
AD  - Department of Critical Care Medicine, The Third Affiliated Hospital of Soochow 
      University, Changzhou, Jiangsu 213003, P.R. China.
FAU - Yu, Hai-Ying
AU  - Yu HY
AD  - Department of Psychiatry, The PLA 102 Hospital, Second Military Medical 
      University, Changzhou, Jiangsu 213003, P.R. China.
FAU - Yan, En-Shi
AU  - Yan ES
AD  - Department of Anesthesiology, Brain Hospital Affiliated to Nanjing Medical 
      University, Nanjing, Jiangsu 210029, P.R. China.
FAU - Zhu, Mei-Hua
AU  - Zhu MH
AD  - Department of Anesthesiology, Brain Hospital Affiliated to Nanjing Medical 
      University, Nanjing, Jiangsu 210029, P.R. China.
FAU - Zhu, Bin
AU  - Zhu B
AD  - Department of Critical Care Medicine, The Third Affiliated Hospital of Soochow 
      University, Changzhou, Jiangsu 213003, P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20131205
PL  - Greece
TA  - Exp Ther Med
JT  - Experimental and therapeutic medicine
JID - 101531947
PMC - PMC3881039
OTO - NOTNLM
OT  - Ca2+/calmodulin-dependent protein kinase 2gamma
OT  - fluvoxamine
OT  - glycogen synthase kinase-3beta
OT  - mammalian target of rapamycin
OT  - sigma1 receptor antagonist
EDAT- 2014/01/08 06:00
MHDA- 2014/01/08 06:01
PMCR- 2013/12/05
CRDT- 2014/01/08 06:00
PHST- 2013/01/20 00:00 [received]
PHST- 2013/11/27 00:00 [accepted]
PHST- 2014/01/08 06:00 [entrez]
PHST- 2014/01/08 06:00 [pubmed]
PHST- 2014/01/08 06:01 [medline]
PHST- 2013/12/05 00:00 [pmc-release]
AID - etm-07-02-0435 [pii]
AID - 10.3892/etm.2013.1438 [doi]
PST - ppublish
SO  - Exp Ther Med. 2014 Feb;7(2):435-438. doi: 10.3892/etm.2013.1438. Epub 2013 Dec 5.